Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)”

41 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 41 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07750574
What this trial is testing

Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis

Who this might be right for
MyelofibrosisMyelofibrosis Due to and Following Polycythemia VeraMyelofibrosis Transformation in Essential Thrombocythemia+9 more
Chengdu Zenitar Biomedical Technology Co., Ltd 105
Large-scale testing (Phase 3)UnknownNCT03662126
What this trial is testing

KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment

Who this might be right for
Primary Myelofibrosis (PMF)Post-Polycythemia Vera MF (Post-PV-MF)Post-Essential Thrombocythemia MF (Post-ET-MF)
Kartos Therapeutics, Inc. 385
Testing effectiveness (Phase 2)UnknownNCT04640532
What this trial is testing

KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF

Who this might be right for
MyelofibrosisPost-PV MFPost-ET Myelofibrosis+1 more
Kartos Therapeutics, Inc. 116
Large-scale testing (Phase 3)Looking for participantsNCT06479135
What this trial is testing

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Who this might be right for
MyelofibrosisPost-PV MFPost-ET Myelofibrosis+2 more
Kartos Therapeutics, Inc. 600
Testing effectiveness (Phase 2)Ended earlyNCT01668173
What this trial is testing

HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET

Who this might be right for
Myeloproliferative Neoplasms
Memorial Sloan Kettering Cancer Center 7
Large-scale testing (Phase 3)Study completedNCT02087059
What this trial is testing

A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis

Who this might be right for
Primary Myelofibrosis (MF)
Novartis Pharmaceuticals 51
Early research (Phase 1)Study completedNCT00910728
What this trial is testing

Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases

Who this might be right for
Primary Myelofibrosis (PMF)Post-Polycythaemia VeraEssential Thrombocythaemia Myelofibrosis
AstraZeneca 65
Testing effectiveness (Phase 2)Active Not RecruitingNCT04446650
What this trial is testing

Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

Who this might be right for
Primary Myelofibrosis
Bristol-Myers Squibb 31
Large-scale testing (Phase 3)Study completedNCT02101268
What this trial is testing

Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF

Who this might be right for
Primary Myelofibrosis (PMF)Post-polycythemia Vera (Post-PV)Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
Sierra Oncology LLC - a GSK company 156
Testing effectiveness (Phase 2)Active Not RecruitingNCT05467800
What this trial is testing

Study of Canakinumab in Patients With Myelofibrosis

Who this might be right for
Primary MyelofibrosisPost-essential Thrombocythemia MyelofibrosisET-MF+2 more
John Mascarenhas 14
Testing effectiveness (Phase 2)Active Not RecruitingNCT03441113
What this trial is testing

Extended Access of Momelotinib in Adults With Myelofibrosis

Who this might be right for
NeoplasmsPost-polycythemia Vera Myelofibrosis (Post-PV MF)Primary Myelofibrosis (PMF)+2 more
GlaxoSmithKline 237
Testing effectiveness (Phase 2)Looking for participantsNCT05835466
What this trial is testing

Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)

Who this might be right for
Myelofibrosis (PMF)Post Essential Thrombocythemia Myelofibrosis (ET-MF)Post Polycythemia Vera Related Myelofibrosis (PV-MF)
Icahn School of Medicine at Mount Sinai 10
Testing effectiveness (Phase 2)UnknownNCT04878003
What this trial is testing

Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis

Who this might be right for
Primary Myelofibrosis (PMF)Post-Polycythemia Vera Myelofibrosis (Post-PV-MF)Post-Essential Thrombocythemia Myelofibrosis (Post-ET-MF)
Kartos Therapeutics, Inc. 52
Testing effectiveness (Phase 2)UnknownNCT01298934
What this trial is testing

LBH589 (Panobinostat) for the Treatment of Myelofibrosis

Who this might be right for
Primary MyelofibrosisPolycythemia Vera, Post-Polycythemic Myelofibrosis PhasePost-Essential Thrombocythemia Related Myelofibrosis
Ronald Hoffman 22
Early research (Phase 1)Active Not RecruitingNCT07340138
What this trial is testing

Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis

Who this might be right for
Primary Myelofibrosis (PMF)Post-polycythemia Vera Myelofibrosis (Post-PV MF)Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
Novartis Pharmaceuticals 3
Testing effectiveness (Phase 2)Study completedNCT04217993
What this trial is testing

Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis

Who this might be right for
Primary Myelofibrosis (PMF)Post-polycythemia Vera Myelofibrosis(Post-PV MF)Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 51
Not applicableStudy completedNCT05044026
What this trial is testing

A Prospective, Two-arm, Non-interventional Study of JAKAVI® (Ruxolitinib) in Patients With Myelofibrosis

Who this might be right for
Primary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis
Novartis Pharmaceuticals 1,012
Testing effectiveness (Phase 2)Study completedNCT02515630
What this trial is testing

Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

Who this might be right for
Primary Myelofibrosis (PMF)Post-polycythemia Vera (Post-PV) MyelofibrosisPostessential Thrombocythemia (Post-ET) Myelofibrosis
Sierra Oncology LLC - a GSK company 41
Early research (Phase 1)Ended earlyNCT03935555
What this trial is testing

Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib

Who this might be right for
Primary Myelofibrosis (PMF)Post-Polycythemia Vera Myelofibrosis (Post-PV MF)Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)
Samus Therapeutics, Inc. 11
Testing effectiveness (Phase 2)Study completedNCT04629508
What this trial is testing

To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)

Who this might be right for
MyelofibrosisPolycythemia VeraThrombocythemia
Incyte Corporation 4
Next Page